Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.

ABSTRACT:

Background and objectives

While randomized, controlled trials (RCTs) are the gold standard for determining treatment efficacy, they do not capture the effectiveness of treatment during real-world use. We aimed to evaluate the association between demographics and multiple sclerosis (MS) disease-modifying therapy (DMT) exposure, including treatment adherence and switches between different DMTs, on the risk of subsequent MS relapse.

Methods

All persons with relapsing-onset MS (pwRMS) living in Manitoba between 1999 and 2014 were identified from provincial healthcare databases using a validated case definition. Use of DMTs was abstracted from the provincial drug database covering all residents of Manitoba, including use of any DMT, stopping/starting any DMT, switches between dif

SUBMITTER: Marriott JJ 

PROVIDER: S-EPMC10511745 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature